



## Gambro BCT's Vista™ Software Receives FDA Market Clearance

**Stockholm, Sweden, July 25, 2002----** Gambro AB (Stockholmsbörsen: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, announced today that its wholly owned subsidiary, Gambro BCT, has received clearance from the US Food and Drug Administration to market Vista <sup>™</sup> - its latest advance in blood center software technology. The introduction of Vista allows Gambro BCT to enter the blood collection software market.

Vista is designed to help blood centers manage business processes and information associated with automated blood collection. Key Vista features include component blood loss tracking, interfaces with collection devices, automated donor management, and business decision support.

"Today, our customers face increasing regulatory and information management challenges," states Michael Seely, Vice President of Gambro BCT US and AMPAC (Americas and Pacific) Sales. "Maintaining multiple systems and the need for manual record keeping increases a center's potential for errors and adds to their work load."

Vista addresses these challenges through unique software, open architecture, and partnerships with key information technology providers that will automate and integrate blood center processes and information. "The combination of Vista software and Gambro BCT's Trima<sup>®</sup> Automated Blood Collection Systems will allow our customers to dramatically increase business productivity, while improving their level of donor care and safety," Seely concludes. Vista and Trima's combined productivity will provide centers with time and money savings, increased product yields, and opportunities to better utilize donors, staff, and equipment.

"Vista represents a cornerstone of our blood bank technology strategy and a tremendous contribution to our customers," states David Perez, President, Gambro BCT, "Gambro BCT customers expect and trust us to provide the highest quality products and services for helping them manage their operations; we at Gambro are committed to meeting those objectives with innovative products such as Vista."

Gambro BCT, headquartered in Lakewood, Colorado, is a world leader in blood bank technologies, automated blood collection, pathogen reduction techniques, and value added blood and cell based therapeutic services.

For further information please contact:
David Perez, President, Gambro BCT, tel +1-303-232-6800
Janette Jennische, Vice President, Corporate Communications, tel. +46-8-613 65 99, +46-70-212 50 53

Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology. Gambro Healthcare is one of the leading providers of kidney dialysis services in the world with more than 52,000 patients in more than 670 clinics worldwide. Gambro Renal Products comprises dialyzers, dialysis machines, blood lines and dialysis concentrates. Gambro BCT is the market leader in separation and handling of blood components. The group, with 2001 revenues of approximately SEK 27 billion (USD 2.7 billion), has 20,500 employees in some 40 countries.

## Gambro AB

A public company (publ)
Reg no. 556041-8005
Jakobsgatan 6, PO Box 7373
SE-103 91 Stockholm
Sweden
Tel +46 8-613 65 00
Fax +46 8-611 28 30
info@gambro.com
www.gambro.com



## **PRESS RELEASE**

July 25, 2002

Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology. Gambro Healthcare is one of the leading providers of kidney dialysis services in the world with more than 52,000 patients in more than 670 clinics worldwide. Gambro Renal Products comprises dialyzers, dialysis machines, blood lines and dialysis concentrates. Gambro BCT is the market leader in separation and handling of blood components. The group, with 2001 revenues of approximately SEK 27 billion (USD 2.7 billion), has 20,500 employees in some 40 countries.

## Gambro AB

A public company (publ) Reg no. 556041-8005 Jakobsgatan 6, PO Box 7373 SE-103 91 Stockholm Sweden Tel +46 8-613 65 00 Fax +46 8-611 28 30 info@gambro.com www.gambro.com